📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
HCG Announces ₹424.68 Crore Rights Issue at ₹512 Per Share
Healthcare Global Enterprises Limited (HCG) is launching a rights issue to raise up to ₹424.68 crore through the issuance of 8.29 million equity shares. The issue price is set at ₹512 per share, and the rights ratio is 1 share for every 17 shares held as of the record date, March 2, 2026. The subscription period is scheduled from March 11 to March 25, 2026, with the last date for on-market renunciation being March 20, 2026.
Key Highlights
Total fundraise of ₹42,468.18 lakhs (approx ₹424.68 crore) via 8.29 million shares.
Rights ratio of 1:17 for eligible shareholders as of the March 2, 2026 record date.
Issue price fixed at ₹512 per share, including a premium of ₹502.
Subscription window opens March 11 and closes March 25, 2026.
💼 Action for Investors
Investors should compare the ₹512 issue price with the prevailing market price; if the market price is higher, they should consider subscribing or selling their rights entitlements by March 20.
HCG Announces ₹424.68 Cr Rights Issue at ₹512/Share; Record Date March 2, 2026
Healthcare Global Enterprises (HCG) has finalized the terms for its rights issue to raise approximately ₹424.68 crore. The company will issue 82,94,566 equity shares at a price of ₹512 per share, which includes a premium of ₹502. The rights entitlement ratio is fixed at 1:17, meaning eligible shareholders can purchase one new share for every 17 shares held as of the record date, March 2, 2026. The issue is scheduled to open on March 11 and close on March 25, 2026.
Key Highlights
Total rights issue size of ₹42,468.18 Lakhs (approx ₹424.68 Cr) for 82,94,566 shares.
Rights issue price set at ₹512 per share, a significant premium over the ₹10 face value.
Entitlement ratio of 1 equity share for every 17 shares held as of March 2, 2026.
Subscription period runs from March 11, 2026, to March 25, 2026.
Post-issue share capital will increase to 14,93,02,203 equity shares assuming full subscription.
💼 Action for Investors
Existing shareholders should decide whether to exercise their rights, renounce them by selling the entitlements on the exchange, or let them lapse. To avoid dilution of value, shareholders should either subscribe to the issue or sell their Rights Entitlements (REs) during the trading window from March 11 to March 20.
HCG to Raise ₹424.68 Crore via Rights Issue at ₹512 per Share; Ratio 1:17
Healthcare Global Enterprises Limited (HCG) has approved a rights issue to raise approximately ₹424.68 crore by issuing 82,94,566 equity shares. The issue is priced at ₹512 per share, and the rights entitlement ratio is fixed at 1:17 for shareholders holding stock as of the record date, March 02, 2026. The subscription period will run from March 11 to March 25, 2026, with the option for shareholders to renounce their rights on the market until March 20, 2026. This move will increase the company's total outstanding equity shares from 14.10 crore to 14.93 crore upon full subscription.
Key Highlights
Rights issue size of ₹424.68 crore at an issue price of ₹512 per share.
Rights entitlement ratio set at 1 equity share for every 17 shares held.
Record date for eligibility is March 02, 2026, with the issue opening on March 11, 2026.
On-market renunciation period ends on March 20, 2026.
Total equity base to expand by approximately 5.88% to 14.93 crore shares.
💼 Action for Investors
Investors should compare the ₹512 issue price with the current market price to determine the attractiveness of the offer. Those not wishing to subscribe should sell their Rights Entitlements (REs) on the exchange before March 20 to avoid the loss of value from the rights dilution.
HCG to Raise ₹424.68 Cr via Rights Issue at ₹512 per Share; Ratio 1:17
Healthcare Global Enterprises Limited (HCG) has finalized terms for its ₹424.68 crore rights issue. Shareholders holding shares on the record date of March 02, 2026, are eligible to apply for 1 new share for every 17 shares held. The issue price is set at ₹512 per share, which includes a premium of ₹502. The subscription window opens on March 11 and closes on March 25, 2026.
Key Highlights
Rights issue of 82,94,566 shares to raise approximately ₹424.68 crore.
Issue price fixed at ₹512 per share with an entitlement ratio of 1:17.
Record date for eligibility is March 02, 2026, with the issue closing on March 25, 2026.
Post-issue equity capital to increase to 14.93 crore shares from 14.10 crore shares.
💼 Action for Investors
Investors should monitor the stock price relative to the ₹512 offer price; if the market price remains significantly higher, exercising rights or selling entitlements is advisable. Ensure action is taken before the March 20 renunciation deadline to prevent loss of value.
HCG Board Approves Rights Issue of Up to ₹425 Crores
The Board of HealthCare Global Enterprises Limited (HCG) has approved a proposal to raise capital up to ₹42,500 Lakhs (₹425 Crores) through a rights issue of equity shares. The issuance will be offered to eligible shareholders as of a record date that is yet to be determined. Key details such as the issue price, rights entitlement ratio, and timing will be finalized by a dedicated Rights Issue Committee. This move indicates a significant capital infusion, likely aimed at strengthening the company's financial position or funding future growth initiatives.
Key Highlights
Board approved issuance of equity shares for an amount not exceeding ₹42,500 Lakhs.
The fundraise will be conducted via a rights issue to existing eligible shareholders.
Equity shares will have a face value of ₹10 each and will be fully paid-up.
Specific terms including issue price and entitlement ratio are to be determined by the Rights Issue Committee.
The announcement follows a board meeting held on February 17, 2026, which concluded at 7:25 p.m.
💼 Action for Investors
Investors should monitor upcoming announcements regarding the rights price and entitlement ratio to evaluate the potential dilution and the attractiveness of the offer. The stock's reaction will likely depend on whether the funds are earmarked for high-growth expansions or debt reduction.
HCG Board Approves Rights Issue to Raise Up to ₹425 Crores
Healthcare Global Enterprises Limited (HCG) has approved a fundraise of up to ₹425 Crores through a rights issue of equity shares. The board meeting held on February 17, 2026, authorized the issuance to eligible shareholders as of a future record date. Details regarding the issue price, entitlement ratio, and timing will be finalized by a dedicated committee. This move is aimed at strengthening the company's capital base for potential expansion or debt management.
Key Highlights
Board approved fundraise not exceeding ₹42,500 Lakhs (₹425 Crores) via a rights issue.
The issue involves fully paid-up equity shares with a face value of ₹10 each.
Specific terms like issue price, entitlement ratio, and record date are yet to be determined by the Rights Issue Committee.
The capital raise is subject to necessary regulatory and statutory approvals.
💼 Action for Investors
Monitor for the announcement of the rights price and entitlement ratio to evaluate the attractiveness of the offer. Long-term investors should assess the company's planned use of proceeds for growth versus debt reduction.
HCG Q3 FY26 Revenue Rises 13.4% to ₹633 Cr; EBITDA Margins Expand to 17.5%
Healthcare Global Enterprises (HCG) reported a steady Q3 FY26 with revenues growing 13.4% YoY to INR 633 crore, despite seasonal softness. Adjusted EBITDA grew 20% YoY to INR 111 crore, with margins expanding by 100 bps to 17.5% due to better operating leverage and digital efficiency. The company is expanding its footprint with a new 120-bed facility in North Bangalore expected in Q4 FY26 and a 60-bed brownfield expansion in Cuttack by FY27. 9M FY26 performance remains strong with a 16% revenue growth and a pre-tax ROCE of 13.3%.
Key Highlights
Q3 FY26 Revenue increased 13.4% YoY to INR 633 crore, while 9M FY26 Revenue reached INR 1,893 crore.
Adjusted EBITDA for the quarter grew 20% YoY to INR 111 crore, with margins improving to 17.5% from 16.5%.
Digital revenue saw a significant 26% YoY growth, with the mobile app scaling 4.5x to contribute 13% of digital sales.
Expansion plans include the 120-bed North Bangalore facility launching in Q4 FY26 and 60 additional beds in Cuttack by FY27.
West cluster led regional growth at 17% YoY, while South cluster grew 9% despite temporary state-scheme disruptions in Andhra Pradesh.
💼 Action for Investors
Investors should monitor the successful commissioning and ramp-up of the North Bangalore facility in Q4 FY26 as a key growth catalyst. The sustained margin expansion and improving ROCE (13.3%) suggest strong operational execution in a specialized oncology market.
HCG Q3FY26 Results: Revenue Up 13% YoY to ₹6,331 Mn, Adjusted EBITDA Jumps 20%
Healthcare Global Enterprises (HCG) reported a strong Q3FY26 with consolidated revenue growing 13% YoY to ₹6,331 Mn. The company's Adjusted EBITDA rose 20% to ₹1,108 Mn, driven by a 98 bps margin expansion to 17.5% due to operating leverage. Adjusted PAT saw a significant increase to ₹70 Mn compared to ₹6 Mn in the previous year's quarter. For the nine-month period, revenue and EBITDA both showed robust growth of 16% and 20% respectively, reflecting steady execution across its oncology network.
Key Highlights
Consolidated Revenue for Q3FY26 grew by 13% YoY to ₹6,331 Mn.
Adjusted EBITDA increased by 20% YoY to ₹1,108 Mn with margins expanding 98 bps to 17.5%.
Adjusted PAT (Post IND AS) surged to ₹70 Mn in Q3FY26 from ₹6 Mn in Q3FY25.
9M FY26 Revenue reached ₹18,931 Mn, a 16% increase over the previous year.
9M FY26 Adjusted EBITDA stood at ₹3,458 Mn, up 20% YoY with margins at 18.3%.
💼 Action for Investors
Investors should take note of the consistent margin expansion and strong EBITDA growth, which demonstrate the scalability of HCG's specialized oncology model. The significant improvement in bottom-line profitability makes it a positive outlook for long-term healthcare portfolios.
HCG Q3FY26 Revenue Grows 13% YoY to INR 6,331 Mn; Adjusted EBITDA Up 20%
Healthcare Global Enterprises (HCG) reported a strong Q3FY26 with consolidated revenue growing 13% YoY to INR 6,331 million. Adjusted EBITDA saw a significant 20% increase to INR 1,108 million, leading to a margin expansion of 100 basis points to 17.5%. Growth was driven by robust performance in the West cluster (+17% revenue) and the Africa business (+42% revenue). The company is also on track to operationalize its new North Bangalore Greenfield Hospital by the end of Q4FY26.
Key Highlights
Q3FY26 Revenue increased 13% YoY to INR 6,331 mn, while 9MFY26 Revenue rose 16% to INR 18,931 mn.
Adjusted EBITDA for Q3FY26 grew 20% YoY to INR 1,108 mn with margins improving to 17.5% from 16.5%.
West cluster revenue grew 17% YoY, supported by volume growth of 11% and expanded capacity in Ahmedabad.
International (Africa) business revenue jumped 42% YoY to INR 157 mn due to ramp-up in radiation oncology.
North Bangalore Greenfield Hospital (120+ beds) featuring MR-LINAC technology is expected to start operations in Q4FY26.
💼 Action for Investors
Investors should monitor the successful ramp-up of the North Bangalore facility and the sustained margin improvement driven by operating leverage. The stock remains a strong play on the specialized oncology segment with improving ROCE and pan-India presence.
HCG Q3FY26 Revenue Up 13% to ₹633 Cr, Adjusted EBITDA Grows 20% YoY
Healthcare Global Enterprises Limited (HCG) reported a robust Q3FY26 with revenue reaching INR 6,331 million, a 13% YoY increase. Adjusted EBITDA grew by 20% YoY to INR 1,108 million, with margins expanding by 100 bps to 17.5% due to operating leverage. The company's 9MFY26 performance remains strong with revenue up 16% and patient volumes increasing by 13%. Expansion is on track with the 120+ bed North Bangalore Greenfield Hospital expected to commence operations by the end of Q4FY26.
Key Highlights
Q3FY26 Revenue grew 13% YoY to INR 6,331 mn; Adjusted EBITDA rose 20% to INR 1,108 mn.
Adjusted EBITDA margins expanded to 17.5% in Q3FY26 from 16.5% in Q3FY25.
The West cluster (45% of revenue) grew 17% YoY, while International business surged 42% YoY.
9MFY26 ARPP (Average Revenue Per Patient) increased by 3% to INR 83,684.
North Bangalore Greenfield Hospital featuring MR-LINAC technology is set to open by Q4FY26 end.
💼 Action for Investors
Investors should focus on the successful commissioning and ramp-up of the North Bangalore facility as a key growth catalyst. The consistent margin expansion and double-digit volume growth reinforce HCG's leadership in the specialized oncology segment.
HCG Appoints Pankaj Gautam as Chief Information Officer to Drive Digital Strategy
Healthcare Global Enterprises Limited (HCG) has announced the appointment of Mr. Pankaj Gautam as Chief Information Officer, effective by February 15, 2026. Mr. Gautam is a veteran with over 20 years of experience in healthcare technology, having previously served at Apollo and Rainbow Children’s Hospitals. His expertise in digital health, EMR platforms, and telehealth is expected to bolster HCG's technology-enabled care delivery. This move strengthens the senior management team as the company focuses on scaling its digital infrastructure.
Key Highlights
Appointment of Mr. Pankaj Gautam as CIO effective on or before February 15, 2026.
Brings over 20 years of experience in healthcare digital transformation and technology strategy.
Previous experience includes leadership roles at Apollo, Glenhealth Works, and Rainbow Children’s Hospitals.
Expertise spans HIS/EMR-EHR platforms, telehealth programs, and healthcare analytics.
💼 Action for Investors
Investors should monitor the impact of new digital initiatives on operational efficiency and patient care delivery. This appointment signals a strong focus on technology-led growth for the oncology chain.
HCG Q3 Standalone Revenue Up 9% YoY to ₹340.6 Cr; Reports Net Loss of ₹1.18 Cr on Exceptional Items
Healthcare Global Enterprises (HCG) reported a standalone revenue of ₹340.6 crore for Q3 FY26, marking a 9.3% growth year-on-year. The company posted a net loss of ₹1.18 crore for the quarter, a significant shift from the ₹10.78 crore profit in the preceding quarter, primarily due to a one-time exceptional charge of ₹7.86 crore related to new Labour Code provisions. On a nine-month basis, the company remains profitable with a net profit of ₹13.05 crore compared to a loss in the previous year. The board also approved a new ESOP scheme and strengthened the senior management team with new appointments in Clinical Strategy and IT.
Key Highlights
Standalone Revenue from Operations increased 9.3% YoY to ₹34,056 lakhs in Q3 FY26.
Reported a Net Loss of ₹118 lakhs for the quarter, impacted by an exceptional item of ₹786 lakhs for gratuity and compensated absences under new Labour Codes.
Profit before exceptional items and tax stood at ₹659 lakhs, down from ₹1,460 lakhs in the preceding quarter.
9M FY26 standalone net profit reached ₹1,305 lakhs, recovering from a net loss of ₹663 lakhs in 9M FY25.
Board approved HCG Employee Stock Option Scheme 2026 and appointed Dr. Naveen R. Nagar as Head of Clinical Strategy and Mr. Pankaj Gautam as CIO.
💼 Action for Investors
Investors should treat the Q3 loss as a non-recurring event driven by regulatory accounting changes rather than operational weakness. The steady YoY revenue growth and 9-month profitability trend suggest the core business remains stable.
HCG Q3 FY26 Standalone Revenue Up 9.3% YoY to ₹340.6 Cr; Reports Net Loss of ₹1.18 Cr
Healthcare Global Enterprises (HCG) reported a 9.3% year-on-year growth in standalone revenue for Q3 FY26, reaching ₹340.6 crore. Despite the revenue growth, the company recorded a standalone net loss of ₹1.18 crore, a significant swing from the ₹10.78 crore profit in the preceding quarter. This loss was primarily driven by a non-recurring exceptional item of ₹7.86 crore related to the adoption of new Labour Codes. The board also approved a new ESOP scheme and strengthened its leadership team with new appointments in clinical strategy and IT.
Key Highlights
Standalone Revenue from operations increased to ₹34,056 lakhs, up 9.3% from ₹31,167 lakhs in the same quarter last year.
Reported a standalone net loss of ₹118 lakhs for the quarter, impacted by exceptional costs.
Exceptional item of ₹786 lakhs recognized due to the incremental impact of new Labour Codes on gratuity and compensated absences.
Board approved the 'HCG Employee Stock Option Scheme, 2026' to grant options to eligible employees.
Appointed Dr. Naveen R. Nagar as Head of Clinical Strategy and Mr. Pankaj Gautam as Chief Information Officer.
💼 Action for Investors
Investors should look past the one-time exceptional loss and focus on the steady 9% YoY revenue growth. Monitor how the new clinical strategy and management appointments impact operational efficiency in the coming quarters.
HCG Shareholders Approve Revised Consultancy Terms for Dr. B.S. Ajaikumar with 98.32% Majority
Healthcare Global Enterprises (HCG) has received shareholder approval for variations to the consultancy arrangement with Dr. B.S. Ajaikumar through a postal ballot. The ordinary resolution passed with a significant majority, with 98.32% of total valid votes cast in favor. While institutional support was robust at 94.37%, there was notable dissent from public non-institutional shareholders, where 31.71% voted against the proposal. This approval formalizes the updated terms for the key leadership figure's advisory role within the company.
Key Highlights
Ordinary resolution for variations to Dr. B.S. Ajaikumar's consultancy arrangement passed with 98.32% favor.
Total valid votes polled amounted to 10.33 crore, representing 73.25% of the total paid-up equity capital.
Institutional investors supported the move with 94.37% of their 2.63 crore polled votes in favor.
Public non-institutional shareholders showed the highest dissent at 31.71% against the resolution.
Promoter and Promoter Group voted 100% in favor of the resolution with 7.62 crore shares.
💼 Action for Investors
Investors should view this as a routine administrative approval that ensures leadership continuity. No immediate portfolio changes are recommended as the resolution aligns with the company's existing management structure.
HCG Seeks Approval to Increase Dr. B.S. Ajaikumar's Consultancy Fee by ‡2 Crore
Healthcare Global Enterprises (HCG) has issued a postal ballot notice to seek shareholder approval for a one-time, non-recurring increase in consultancy fees for Dr. B.S. Ajaikumar. The proposed increase of INR 2 crore for FY 2025-26 is intended to compensate for additional services including transition support following management changes and the retention of key medical talent. The remote e-voting period for this ordinary resolution is scheduled from December 23, 2025, to January 21, 2026, with final results expected by January 23, 2026.
Key Highlights
Proposed one-time increase of INR 2,00,00,000 (2 Crores) in consultancy fees for Dr. B.S. Ajaikumar for FY 2025-26.
The additional fee covers transition support, administrative assistance, and clinical talent retention strategies.
The underlying consultancy agreement is proposed to remain valid until June 30, 2030.
E-voting period runs from December 23, 2025, to January 21, 2026, for all eligible shareholders as of the December 19 cut-off date.
💼 Action for Investors
Investors should review the rationale for this related party transaction and participate in the e-voting process to ensure executive compensation remains aligned with company performance.
HCG appoints Dr. Manish Mattoo as interim CFO, effective Dec 1, 2025
Healthcare Global Enterprises Limited (HCG) has appointed Dr. Manish Mattoo, Executive Director and CEO, as the interim Chief Financial Officer (CFO) and Key Managerial Personnel, effective December 1, 2025. This appointment follows the recommendation of the Audit Committee and the Nomination and Remuneration Committee. Dr. Mattoo's term will last until a new CFO is appointed by the Board. He previously served as Regional Chief Executive Officer at Apollo Hospitals, overseeing 2000+ beds.
Key Highlights
Dr. Manish Mattoo appointed as interim CFO effective December 1, 2025
Dr. Mattoo previously led a team of over 6,000 associates at Apollo Hospitals.
Dr. Mattoo oversaw 2000+ beds as Regional CEO at Apollo Hospitals.
Board meeting concluded at 2:55 p.m. (IST) on December 01, 2025.
💼 Action for Investors
Investors should monitor the appointment of a permanent CFO and assess any impact on the company's financial strategy. This is a transitional appointment and is unlikely to cause any immediate change.